188 related articles for article (PubMed ID: 30312735)
1. Aptamer-based proteomics of serum and plasma in acquired aplastic anemia.
Giudice V; Biancotto A; Wu Z; Cheung F; Candia J; Fantoni G; Kajigaya S; Rios O; Townsley D; Feng X; Young NS
Exp Hematol; 2018 Dec; 68():38-50. PubMed ID: 30312735
[TBL] [Abstract][Full Text] [Related]
2. Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy.
Yamazaki H; Ohta K; Iida H; Imada K; Obara N; Tokumine Y; Tomiyama Y; Usuki K; Imajo K; Miyamura K; Sasaki O; Fanghong Z; Hattori T; Tajima T; Matsuda A; Nakao S
Int J Hematol; 2019 Aug; 110(2):187-196. PubMed ID: 31183813
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal evaluation of eltrombopag in paediatric acquired severe aplastic anaemia.
Filippidou M; Avgerinou G; Tsipou H; Tourkantoni N; Katsibardi K; Vlachou A; Roka K; Solomou E; Kattamis A
Br J Haematol; 2020 Aug; 190(3):e157-e159. PubMed ID: 32529633
[No Abstract] [Full Text] [Related]
4. Eltrombopag in children with severe aplastic anemia.
Lesmana H; Jacobs T; Boals M; Gray N; Lewis S; Ding J; Kang G; Hale M; Weiss M; Reiss U; Wang W; Wlodarski M
Pediatr Blood Cancer; 2021 Aug; 68(8):e29066. PubMed ID: 33855784
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
Townsley DM; Scheinberg P; Winkler T; Desmond R; Dumitriu B; Rios O; Weinstein B; Valdez J; Lotter J; Feng X; Desierto M; Leuva H; Bevans M; Wu C; Larochelle A; Calvo KR; Dunbar CE; Young NS
N Engl J Med; 2017 Apr; 376(16):1540-1550. PubMed ID: 28423296
[TBL] [Abstract][Full Text] [Related]
6. Markedly High Plasma Thrombopoietin (TPO) Level is a Predictor of Poor Response to Immunosuppressive Therapy in Children With Acquired Severe Aplastic Anemia.
Elmahdi S; Muramatsu H; Narita A; Ismael O; Hama A; Nishio N; Okuno Y; Xu Y; Wang X; Takahashi Y; Kojima S
Pediatr Blood Cancer; 2016 Apr; 63(4):659-64. PubMed ID: 26575027
[TBL] [Abstract][Full Text] [Related]
7. Activity of eltrombopag in severe aplastic anemia.
Scheinberg P
Blood Adv; 2018 Nov; 2(21):3054-3062. PubMed ID: 30425070
[TBL] [Abstract][Full Text] [Related]
8. Upfront eltrombopag monotherapy induces stable hematologic remission in pediatric patients with nonsevere idiopathic aplastic anemia.
Geng W; Kearney S; Nelson S
Pediatr Blood Cancer; 2018 Oct; 65(10):e27290. PubMed ID: 29932285
[TBL] [Abstract][Full Text] [Related]
9. Aplastic Anemia.
Young NS
N Engl J Med; 2018 Oct; 379(17):1643-1656. PubMed ID: 30354958
[No Abstract] [Full Text] [Related]
10. Activity of eltrombopag in severe aplastic anemia.
Scheinberg P
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):450-456. PubMed ID: 30504345
[TBL] [Abstract][Full Text] [Related]
11. [Recent issues and prospects of the treatment of aplastic anemia].
Nakao S
Rinsho Ketsueki; 2014 Jan; 55(1):5-11. PubMed ID: 24492031
[No Abstract] [Full Text] [Related]
12. [Thrombopoietin receptor agonist arouses new hope].
Häckel A
MMW Fortschr Med; 2016 Apr; 158(7):73. PubMed ID: 27071600
[No Abstract] [Full Text] [Related]
13. Eltrombopag in aplastic anemia.
Desmond R; Townsley DM; Dunbar C; Young NS
Semin Hematol; 2015 Jan; 52(1):31-7. PubMed ID: 25578417
[TBL] [Abstract][Full Text] [Related]
14. Elevated Serum Interleukin-6 Predicts Favorable Response to Immunosuppressive Therapy in Children With Aplastic Anemia.
Lu S; Qiao X; Xie X
J Pediatr Hematol Oncol; 2017 Nov; 39(8):614-617. PubMed ID: 29068868
[TBL] [Abstract][Full Text] [Related]
15. Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study.
Peffault de Latour R; Huynh L; Ivanova JI; Totev T; Bilginsoy M; Antin J; Roy A; Duh MS
Ann Hematol; 2020 Apr; 99(4):743-752. PubMed ID: 32065291
[TBL] [Abstract][Full Text] [Related]
16. Post-therapeutic recovery of serum interleukin-35 level might predict positive response to immunosuppressive therapy in pediatric aplastic anemia.
Huang Z; Tong H; Li Y; Zhou H; Qian J; Wang J; Ruan J
Hematology; 2017 Aug; 22(7):430-436. PubMed ID: 28211781
[TBL] [Abstract][Full Text] [Related]
17. Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag.
Fattizzo B; Kulasekararaj AG; Hill A; Benson-Quarm N; Griffin M; Munir T; Arnold L; Riley K; Ireland R; De Lavallade H; Potter V; Consonni D; Hillmen P; Mufti GJ; Barcellini W; Marsh JCW
Haematologica; 2019 Nov; 104(11):e494-e496. PubMed ID: 30890599
[No Abstract] [Full Text] [Related]
18. The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study.
Ames NJ; Barb JJ; Ranucci A; Kim H; Mudra SE; Cashion AK; Townsley DM; Childs R; Paster BJ; Faller LL; Wallen GR
Ann Hematol; 2019 Jun; 98(6):1351-1365. PubMed ID: 30919073
[TBL] [Abstract][Full Text] [Related]
19. Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience. German/Austrian Pediatric Aplastic Anemia Working Group.
Führer M; Burdach S; Ebell W; Gadner H; Haas R; Harbott J; Janka-Schaub G; Klingebiel T; Kremens B; Niemeyer C; Rampf U; Reiter A; Ritter J; Schulz A; Walther U; Zeidler C; Bender-Götze C
Klin Padiatr; 1998; 210(4):173-9. PubMed ID: 9743949
[TBL] [Abstract][Full Text] [Related]
20. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.
Assi R; Garcia-Manero G; Ravandi F; Borthakur G; Daver NG; Jabbour E; Burger J; Estrov Z; Dinardo CD; Alvarado Y; Hendrickson S; Ferrajoli A; Wierda W; Cortes J; Kantarjian H; Kadia TM
Cancer; 2018 Nov; 124(21):4192-4201. PubMed ID: 30307606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
